微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 58.41% | 29.84% | 5.1% | 52/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 55.58% | 26.49% | 9.26% | 63/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 50.87% | 20.73% | 13.46% | 73/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 44.83% | 5.6% | -0.34% | 89/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 44.99% | 9.26% | 2.39% | 86/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 43.94% | 11.6% | 4.28% | 88/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 42.13% | 16.54% | -0.76% | 88/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 42.46% | 2.2% | 3.11% | 95/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 41.18% | -0.3% | 4.58% | 95/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 39.37% | -5.27% | 8.9% | 99/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 36.15% | -10.16% | -12.97% | 105/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 41.54% | -0.75% | 0.59% | 101/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 41.3% | 0.67% | -0.63% | 99/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 41.56% | 3.46% | 3.28% | 101/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 40.24% | 2.36% | -3.86% | 97/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 41.86% | 2.62% | 2.03% | 99/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 41.02% | 1.19% | 2.12% | 94/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 40.17% | -1.79% | 2.18% | 99/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 39.31% | -0.92% | -3.61% | 94/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 40.79% | -5.75% | 0.6% | 100/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 40.54% | -8.39% | -0.88% | 88/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 40.9% | -11.34% | 3.08% | 95/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 39.68% | -9.63% | -8.3% | 85/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 43.27% | 0.71% | -2.22% | 97/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 44.26% | -1.95% | -4.07% | 81/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 46.13% | 0.13% | 5.07% | 83/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 43.91% | -1.01% | 2.19% | 74/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 42.97% | 2.85% | -4.8% | 90/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 45.14% | 15.24% | -2.03% | 68/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 46.07% | 20.29% | 3.86% | 68/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 44.36% | 26.07% | 6.18% | 66/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 41.78% | 32.53% | 6.66% | 89/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 39.17% | 35.73% | 2.26% | 72/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 38.3% | 36.57% | 8.86% | 76/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 35.18% | 28.06% | 11.62% | 77/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 31.52% | 13.91% | 9.24% | 95/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 28.86% | 8.72% | 2.89% | 78/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 28.04% | 4.19% | 2.08% | 82/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 27.47% | 2.15% | -0.71% | 69/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 27.67% | -0.58% | 4.26% | 94/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 26.54% | 1.45% | -1.39% | 66/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 26.92% | 1.27% | 0.08% | 73/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 26.9% | 9.36% | -3.37% | 62/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |